2022 - Clinically-Relevant Biomarker Strategies in Drug Development and the Potential of Machine-Learning for Biomarker Assessment

Biomarker quantification plays an integral role in the drug development process, providing guidance for downstream decision-making that has shown to correlate positively with clinical trial success. Biomarker-based stratification enriches clinical populations, reducing cost and trial duration. However, the real value of biomarker insights have not been fully realized due the limitations in the development and implementation of effective biomarker strategies in many clinical programmes across therapeutic areas, resulting in the absence of predictive biomarkers in the latest drug approvals.
It is also worth considering the prospect of applying machine-learning to biomarker assessment, which promises improved patient stratification of treatment response to drive drug development.
Register to learn about the importance of utilising biomarkers within clinical trials and how to go about developing effective biomarker strategies.